ATP13A4

Summary

ATP13A4 (ATPase 13A4, HGNC:25422) is a protein-coding gene on chromosome 3q29, encoding Probable cation-transporting ATPase 13A4 (Q4VNC1).

Predicted to enable ATPase-coupled monoatomic cation transmembrane transporter activity and polyamine transmembrane transporter activity. Predicted to be involved in intracellular calcium ion homeostasis and polyamine transmembrane transport. Predicted to be located in early endosome membrane and recycling endosome membrane. Predicted to be active in endoplasmic reticulum membrane and late endosome membrane.

Source: NCBI Gene 84239 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 237 total — 2 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_032279

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25422
Approved symbol	ATP13A4
Name	ATPase 13A4
Location	3q29
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp761I1011, FLJ37958
Ensembl gene	ENSG00000127249
Ensembl biotype	protein_coding
OMIM	609556
Entrez	84239

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 3 nonsense_mediated_decay, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000295548, ENST00000342695, ENST00000392443, ENST00000400270, ENST00000428352, ENST00000437904, ENST00000450950, ENST00000474776, ENST00000482964, ENST00000489140, ENST00000490925, ENST00000901816

RefSeq mRNA: 1 — MANE Select: NM_032279 NM_032279

CCDS: CCDS3304

Canonical transcript exons

ENST00000342695 — 30 exons

Exon	Start	End
ENSE00001867799	193554740	193554895
ENSE00003459588	193502493	193502639
ENSE00003462038	193459081	193459231
ENSE00003463486	193514698	193514871
ENSE00003471113	193438475	193438584
ENSE00003486915	193483936	193484005
ENSE00003494906	193440558	193440637
ENSE00003497871	193492917	193492997
ENSE00003503435	193414579	193414750
ENSE00003504086	193433845	193433917
ENSE00003508741	193454101	193454212
ENSE00003529407	193467316	193467486
ENSE00003544863	193466025	193466182
ENSE00003548851	193493090	193493160
ENSE00003562890	193457000	193457153
ENSE00003579536	193442393	193442556
ENSE00003584997	193435648	193435744
ENSE00003593657	193457379	193457465
ENSE00003594001	193412178	193412371
ENSE00003601588	193491329	193491398
ENSE00003624119	193489730	193489864
ENSE00003624698	193470859	193470993
ENSE00003642740	193448206	193448330
ENSE00003654785	193407313	193407393
ENSE00003662706	193410982	193411070
ENSE00003663744	193462762	193462823
ENSE00003684948	193464940	193465128
ENSE00003690642	193439023	193439065
ENSE00003692053	193441466	193441588
ENSE00003845789	193398967	193402864

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 99.11.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1445 / max 274.5619, expressed in 522 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
46169	1.0460	409
46163	0.7204	155
46162	0.5536	135
46166	0.2966	87
46164	0.1963	80
46167	0.1232	60
46168	0.1182	68
46165	0.0903	45

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.11	gold quality
right lobe of thyroid gland	UBERON:0001119	97.96	gold quality
left lobe of thyroid gland	UBERON:0001120	97.27	gold quality
thyroid gland	UBERON:0002046	97.11	gold quality
right lung	UBERON:0002167	96.10	gold quality
upper lobe of left lung	UBERON:0008952	94.26	gold quality
upper lobe of lung	UBERON:0008948	93.65	gold quality
lower esophagus mucosa	UBERON:0035834	93.56	gold quality
epithelial cell of pancreas	CL:0000083	92.76	gold quality
lung	UBERON:0002048	91.89	gold quality
right uterine tube	UBERON:0001302	91.29	gold quality
upper arm skin	UBERON:0004263	91.16	gold quality
esophagus squamous epithelium	UBERON:0006920	90.98	gold quality
palpebral conjunctiva	UBERON:0001812	90.86	gold quality
esophagus mucosa	UBERON:0002469	90.68	gold quality
skin of leg	UBERON:0001511	90.64	gold quality
medial globus pallidus	UBERON:0002477	90.64	gold quality
corpus epididymis	UBERON:0004359	90.39	gold quality
corpus callosum	UBERON:0002336	90.26	gold quality
globus pallidus	UBERON:0001875	89.68	gold quality
skin of abdomen	UBERON:0001416	89.36	gold quality
lateral globus pallidus	UBERON:0002476	88.81	gold quality
amygdala	UBERON:0001876	88.34	gold quality
visceral pleura	UBERON:0002401	88.34	gold quality
zone of skin	UBERON:0000014	88.21	gold quality
nucleus accumbens	UBERON:0001882	88.17	gold quality
caudate nucleus	UBERON:0001873	88.06	gold quality
gingival epithelium	UBERON:0001949	87.88	gold quality
putamen	UBERON:0001874	86.48	gold quality
gingiva	UBERON:0001828	86.09	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-75688	yes	359.03
E-HCAD-25	yes	22.13
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

117 targeting ATP13A4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-3934-5P	99.67	64.04	846

Literature-anchored findings (GeneRIF, showing 3)

• ATP13A4 is a novel gene coding for a cation-transporting P-type ATPase and is interrupted by 3q25-q29 inversion in an individual with language delay (PMID:15925480)
• mRNA expression of the P5 ATPase ATP13A4 is increased in Broca’s area from subjects with schizophrenia. (PMID:30501451)
• ATP13A4 Upregulation Drives the Elevated Polyamine Transport System in the Breast Cancer Cell Line MCF7. (PMID:37371498)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp1a3a	ENSDARG00000018259
danio_rerio	atp2b2	ENSDARG00000063433
danio_rerio	atp1a3b	ENSDARG00000104139
mus_musculus	Atp13a4	ENSMUSG00000038094
rattus_norvegicus	Atp13a4	ENSRNOG00000001714
drosophila_melanogaster	anne	FBGN0052000
drosophila_melanogaster	SPoCk	FBGN0052451
drosophila_melanogaster	CG45062	FBGN0266432
drosophila_melanogaster	CG45063	FBGN0266433
caenorhabditis_elegans		WBGENE00000834
caenorhabditis_elegans	pmr-1	WBGENE00004063
caenorhabditis_elegans		WBGENE00012341
caenorhabditis_elegans		WBGENE00015338
caenorhabditis_elegans		WBGENE00015660

Paralogs (21): ATP2C1 (ENSG00000017260), ATP1A2 (ENSG00000018625), ATP2B4 (ENSG00000058668), ATP2C2 (ENSG00000064270), ATP2B3 (ENSG00000067842), ATP2B1 (ENSG00000070961), ATP2A3 (ENSG00000074370), ATP12A (ENSG00000075673), ATP1A3 (ENSG00000105409), ATP4A (ENSG00000105675), ATP13A1 (ENSG00000105726), ATP7B (ENSG00000123191), ATP1A4 (ENSG00000132681), ATP13A3 (ENSG00000133657), ATP2B2 (ENSG00000157087), ATP13A2 (ENSG00000159363), ATP1A1 (ENSG00000163399), ATP7A (ENSG00000165240), ATP2A2 (ENSG00000174437), ATP13A5 (ENSG00000187527), ATP2A1 (ENSG00000196296)

Protein

Protein identifiers

Probable cation-transporting ATPase 13A4 — Q4VNC1 (reviewed: Q4VNC1)

Alternative names: P5-ATPase isoform 4

All UniProt accessions (5): Q4VNC1, B7WPN9, F8W9W3, H0Y4Z2, H7C1P5

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Early endosome membrane. Late endosome membrane. Recycling endosome membrane.

Tissue specificity. Expressed in heart, placenta, liver, skeletal muscles, and pancreas. Lower levels of expression are also detected in brain, lung and kidney. Weakly expressed in the adult brain. Expression in fetal brain is higher than in adult brain, with levels similar to several other fetal tissues including spleen and skeletal muscle. In adult brain expressed at low levels in all tissues examined, including the temporal lobe and putamen. Highly expressed in the respiratory and integumentary systems.

Disease relevance. A chromosomal aberration involving ATP13A4 is found in 2 patients with specific language impairment (SLI) disorders. Paracentric inversion inv(3)(q25;q29). The inversion produces a disruption of the protein.

Induction. Decreased by half in the SLI patient lymphoblasts.

Miscellaneous. Dubious isoform lacking mature mRNA evidence.

Similarity. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type V subfamily.

Isoforms (4)

UniProt ID	Names	Canonical?
Q4VNC1-1	1	yes
Q4VNC1-2	2
Q4VNC1-3	3
Q4VNC1-4	4

RefSeq proteins (1): NP_115655* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001757	P_typ_ATPase	Family
IPR004014	ATPase_P-typ_cation-transptr_N	Domain
IPR006544	P-type_TPase_V	Family
IPR008250	ATPase_P-typ_transduc_dom_A_sf	Homologous_superfamily
IPR018303	ATPase_P-typ_P_site	PTM
IPR023214	HAD_sf	Homologous_superfamily
IPR023298	ATPase_P-typ_TM_dom_sf	Homologous_superfamily
IPR023299	ATPase_P-typ_cyto_dom_N	Homologous_superfamily
IPR036412	HAD-like_sf	Homologous_superfamily
IPR044492	P_typ_ATPase_HD_dom	Domain
IPR047819	P5A-ATPase_N	Domain
IPR047821	P5B-type_ATPase	Family
IPR059000	ATPase_P-type_domA	Domain

Pfam: PF00122, PF00690, PF12409, PF13246

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (36 total): topological domain 12, transmembrane region 10, splice variant 4, sequence variant 3, binding site 2, sequence conflict 2, chain 1, intramembrane region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q4VNC1-F1	80.48	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 486 (4-aspartylphosphate intermediate)

Ligand- & substrate-binding residues (2): 848; 852

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-382551	Transport of small molecules
R-HSA-983712	Ion channel transport

MSigDB gene sets: 138 (showing top): BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, NKX25_02, CAGCTG_AP4_Q5, GOBP_MONOATOMIC_CATION_TRANSPORT, OCT1_07, GATA1_03, GOBP_MONOATOMIC_ION_HOMEOSTASIS, POU3F2_02, RFX1_02, VECCHI_GASTRIC_CANCER_EARLY_DN, TGTYNNNNNRGCARM_UNKNOWN, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_LATE_ENDOSOME_MEMBRANE, GOCC_EARLY_ENDOSOME_MEMBRANE, GOBP_HOMEOSTATIC_PROCESS

GO Biological Process (5): intracellular calcium ion homeostasis (GO:0006874), monoatomic ion transmembrane transport (GO:0034220), polyamine transmembrane transport (GO:1902047), transmembrane transport (GO:0055085), monoatomic cation transmembrane transport (GO:0098655)

GO Molecular Function (9): ATP binding (GO:0005524), polyamine transmembrane transporter activity (GO:0015203), P-type ion transporter activity (GO:0015662), ATP hydrolysis activity (GO:0016887), ATPase-coupled monoatomic cation transmembrane transporter activity (GO:0019829), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), transporter activity (GO:0005215), P-type transmembrane transporter activity (GO:0140358)

GO Cellular Component (7): endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), early endosome membrane (GO:0031901), late endosome membrane (GO:0031902), recycling endosome membrane (GO:0055038), endosome (GO:0005768), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Ion channel transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endosome membrane	3
transmembrane transport	2
ATPase-coupled transmembrane transporter activity	2
intracellular monoatomic cation homeostasis	1
calcium ion homeostasis	1
monoatomic ion transport	1
polyamine transport	1
transport	1
cellular process	1
monoatomic cation transport	1
monoatomic ion transmembrane transport	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
transmembrane transporter activity	1
polyamine transmembrane transport	1
P-type transmembrane transporter activity	1
ribonucleoside triphosphate phosphatase activity	1
ATP-dependent activity	1
monoatomic cation transmembrane transporter activity	1
active monoatomic ion transmembrane transporter activity	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
early endosome	1
late endosome	1
recycling endosome	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1256 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP13A4	ZNF169	Q14929	508
ATP13A4	SLC38A4	Q969I6	452
ATP13A4	SLC67A1	Q96BI1	410
ATP13A4	KIAA0319	Q5VV43	403
ATP13A4	OR2A2	Q6IF42	398
ATP13A4	DUSP22	Q9NRW4	396
ATP13A4	AGPAT2	O15120	391
ATP13A4	SPATA31A6	Q5VVP1	379
ATP13A4	H6PD	O95479	351
ATP13A4	OR56A4	Q8NGH8	348
ATP13A4	SLC12A8	A0AV02	345
ATP13A4	ATP13A1	Q9HD20	345
ATP13A4	CNTNAP1	P78357	338
ATP13A4	GAK	O14976	334
ATP13A4	CNTNAP2	Q9UHC6	332

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ATP13A4	HES4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (1): ATP13A4 (Proximity Label-MS)

ESM2 similar proteins: A1A4J6, D4ABB8, F1Q4S1, G5EBH1, O14072, O43520, O43861, O70228, O75110, P09626, P19156, P20648, P27112, P40527, P50996, P57792, P90747, P98195, P98196, P98197, P98198, P98199, Q10309, Q27533, Q3TYU2, Q4VNC1, Q4WYP6, Q5XF89, Q5XF90, Q5ZKB7, Q64436, Q6DFW5, Q8NB49, Q92126, Q93084, Q95JN5, Q9EPE9, Q9H7F0, Q9HD20, Q9LI83

Diamond homologs: O14022, O74431, P0ABB8, P0ABB9, P22036, P54211, Q12697, Q21286, Q27533, Q3TYU2, Q4VNC0, Q4VNC1, Q5XF89, Q5XF90, Q5ZKB7, Q95JN5, Q9CTG6, Q9H7F0, Q9NQ11, O14072, P13587, P39986, P90747, Q01896, Q04956, Q12691, Q9EPE9, Q9HD20, P22180, P23980, P54679, Q08435, Q08436, Q43128, Q58623, Q9LV11, Q9LY32, Q9SH76, Q9SU58, P57698

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

237 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	176
Likely benign	24
Benign	11

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3247018	NC_000003.11:g.(?193207380)(193409916_?)del	Pathogenic
562855	GRCh37/hg19 3q28-29(chr3:187913567-197851986)x3	Pathogenic
545290	NC_000003.12:g.(?187222939)(194312782_?)del	Likely pathogenic

SpliceAI

5244 predictions. Top by Δscore:

Variant	Effect	Δscore
3:193433843:A:AC	donor_gain	1.0000
3:193433844:C:CC	donor_gain	1.0000
3:193440556:A:AC	donor_gain	1.0000
3:193440557:C:CC	donor_gain	1.0000
3:193441459:AACTT:A	donor_loss	1.0000
3:193441460:ACTTA:A	donor_loss	1.0000
3:193441461:CTTAC:C	donor_loss	1.0000
3:193441462:TTA:T	donor_loss	1.0000
3:193441463:TACCT:T	donor_loss	1.0000
3:193441464:A:C	donor_loss	1.0000
3:193441465:C:A	donor_loss	1.0000
3:193441588:CCTA:C	acceptor_loss	1.0000
3:193441589:CTAC:C	acceptor_loss	1.0000
3:193441590:T:G	acceptor_loss	1.0000
3:193441856:CAAG:C	acceptor_gain	1.0000
3:193448202:ATACC:A	donor_loss	1.0000
3:193448205:C:CT	donor_loss	1.0000
3:193451548:AAGC:A	donor_gain	1.0000
3:193454208:GGGTA:G	acceptor_gain	1.0000
3:193454209:GGTA:G	acceptor_gain	1.0000
3:193454210:GTA:G	acceptor_gain	1.0000
3:193454211:TA:T	acceptor_gain	1.0000
3:193454212:AC:A	acceptor_loss	1.0000
3:193454213:C:CA	acceptor_loss	1.0000
3:193454213:C:CC	acceptor_gain	1.0000
3:193467311:CTAA:C	donor_loss	1.0000
3:193467313:AACC:A	donor_loss	1.0000
3:193467314:A:C	donor_loss	1.0000
3:193467315:C:G	donor_loss	1.0000
3:193467315:CCAGT:C	donor_gain	1.0000

AlphaMissense

7865 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:193439029:G:C	D852E	0.999
3:193439029:G:T	D852E	0.999
3:193439030:T:A	D852V	0.999
3:193439030:T:G	D852A	0.999
3:193439030:T:C	D852G	0.998
3:193439031:C:G	D852H	0.998
3:193464944:T:A	D486V	0.998
3:193433888:A:C	F933L	0.997
3:193433888:A:T	F933L	0.997
3:193433890:A:G	F933L	0.997
3:193435684:G:C	S911R	0.997
3:193435684:G:T	S911R	0.997
3:193435686:T:G	S911R	0.997
3:193435736:C:G	R894P	0.997
3:193439045:C:T	G847D	0.997
3:193442526:G:T	A728D	0.997
3:193442527:C:G	A728P	0.997
3:193464944:T:G	D486A	0.997
3:193464951:A:G	C484R	0.997
3:193464956:A:G	L482P	0.997
3:193465076:A:T	V442D	0.997
3:193489819:A:G	W217R	0.997
3:193489819:A:T	W217R	0.997
3:193489829:A:C	S213R	0.997
3:193489829:A:T	S213R	0.997
3:193489831:T:G	S213R	0.997
3:193438571:G:T	A859D	0.996
3:193440612:G:T	A822E	0.996
3:193442553:T:A	D719V	0.996
3:193457112:G:C	F601L	0.996

dbSNP variants (sampled 300 via entrez): RS1000028191 (3:193470547 A>T), RS1000050929 (3:193407253 T>C), RS1000056930 (3:193547038 A>G), RS1000068344 (3:193452662 A>G), RS1000081943 (3:193470721 C>A,T), RS1000083772 (3:193452890 T>A,C,G), RS1000145938 (3:193447391 G>A), RS1000151355 (3:193594012 C>A,G), RS1000156830 (3:193498936 A>C,G,T), RS1000175350 (3:193560929 T>A), RS1000193161 (3:193528780 C>A), RS1000206070 (3:193561251 C>T), RS1000211788 (3:193426667 G>A,C), RS1000214788 (3:193494272 C>T), RS1000242683 (3:193426461 G>A,T)

Disease associations

OMIM: gene MIM:609556 | disease phenotypes: MIM:181500, MIM:117000

GenCC curated gene-disease

Mondo (2): schizophrenia (MONDO:0005090), central core myopathy (MONDO:0007294)

Orphanet (2): Central core disease (Orphanet:597), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009820_1	Obsession score in obsessive compulsive disorder	9.000000e-06
GCST012095_24	Major depressive episode treated with electroconvulsive therapy	3.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007802	obsessive-compulsive symptom measurement
EFO:0007634	major depressive episode

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D020512	Myopathy, Central Core	C05.651.575.300; C10.668.491.550.300

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — P5 P-type ATPases: Mn²⁺-ATPases

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
methyleugenol	decreases expression	1
trichostatin A	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
dorsomorphin	increases expression, affects cotreatment	1
licochalcone B	increases expression	1
bisphenol S	decreases expression	1
Panobinostat	affects cotreatment, increases expression	1
Carbamazepine	affects expression	1
Estradiol	decreases expression	1
Formaldehyde	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Rotenone	increases expression	1
Testosterone	decreases expression	1
Valproic Acid	affects cotreatment, increases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety